Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Traws Pharma (TRAW) Net Margin (2016 - 2025)

Traws Pharma (TRAW) has disclosed Net Margin for 14 consecutive years, with 8.16% as the latest value for Q2 2025.

  • On a quarterly basis, Net Margin rose 3643745.0% to 8.16% in Q2 2025 year-over-year; TTM through Sep 2025 was 337.1%, a 1635183.0% increase, with the full-year FY2024 number at 24192.04%, down 1580796.0% from a year prior.
  • Net Margin was 8.16% for Q2 2025 at Traws Pharma, down from 26461.4% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 26461.4% in Q1 2025 to a low of 38248.21% in Q4 2024.
  • A 5-year average of 9453.6% and a median of 8118.42% in 2021 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: crashed -3028036bps in 2024, then surged 3643745bps in 2025.
  • Traws Pharma's Net Margin stood at 6719.64% in 2021, then crashed by -52bps to 10239.29% in 2022, then grew by 22bps to 7967.86% in 2023, then plummeted by -380bps to 38248.21% in 2024, then skyrocketed by 100bps to 8.16% in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Net Margin are 8.16% (Q2 2025), 26461.4% (Q1 2025), and 38248.21% (Q4 2024).